IV.a
Bronchospasm - Wheezing - Asthma
(Fr: bronchospasme, asthme). Including bronchospasm, bronchoconstriction, de novo subacute asthma, asthma attack and deterioration or exacerbation of preexisting/underlying asthma. Can be sudden and very severe, causing asphyxia followed by irreversible hypoxic brain damage (see also under IVf). NSAIDs, ß-blockers and antibiotics are the main causal agents. Patients with a background of atopy or asthma are particularly at risk. In a few individuals, the asthma may persist despite cessation of exposure (PMID 45308). Healthcare workers can be involved when handling drugs (PMID 3612323). Workers in the drug-manufacturing (e.g. antibiotics) industry can develop bronchospasm or asthma as a manifestation of drug-induced occupational disease (PMID 16436155, 21603168, 30075340)
Causative drugs
Timolol
I.b - Pneumonitis (ILD) I.d I - Interstitial/parenchymal lung disease
I.d - Organizing pneumonia pattern (an area or areas of consolidation on imaging) IV.a IV - Airway involvement
IV.a - Bronchospasm - Wheezing - Asthma IV.f IV - Airway involvement
IV.f - Severe or catastrophic bronchospasm or asthma attack (can be fatal) V.d V - Pleural and/or pericardial involvement
V.d - Pleural/pericardial effusion, ANA positive (DI lupus) IX.d IX - Neuromuscular / CNS involvement - Disordered breathing during sleep
IX.d - Respiratory failure from ventilatory depression (due to neuromuscular blockade/paralysis)
Tobacco smoke - Cigarette smoking
I.c - Eosinophilic pneumonia (pulmonary infiltrates and eosinophilia) I.e I - Interstitial/parenchymal lung disease
I.e - Acute eosinophilic pneumonia (AEP) I.g I - Interstitial/parenchymal lung disease
I.g - Pulmonary fibrosis I.h I - Interstitial/parenchymal lung disease
I.h - Subclinical pulmonary infiltrates/ILD I.j I - Interstitial/parenchymal lung disease
I.j - Exogenous lipoid pneumonia (subacute, acute) I.r I - Interstitial/parenchymal lung disease
I.r - An imaging pattern consistent with DIP I.ai I - Interstitial/parenchymal lung disease
I.ai - Combined pulmonary fibrosis and emphysema syndrome (CPFE) IV.a IV - Airway involvement
IV.a - Bronchospasm - Wheezing - Asthma IV.d IV - Airway involvement
IV.d - Cough (lone) IV.g IV - Airway involvement
IV.g - Cough syncope IV.n IV - Airway involvement
IV.n - Obstructive airway dysfunction (see also IVc, XVx) IV.u IV - Airway involvement
IV.u - Endobronchial (eosinophilic) nodules on bronchoscopy IV.ad IV - Airway involvement
IV.ad - Large airway inflammation - Tracheitis (w/wo tissue eosinophilia) IX.q IX - Neuromuscular / CNS involvement - Disordered breathing during sleep
IX.q - Obstructive sleep apnea X.m X - Systemic/Distant conditions, syndromes and reactions
X.m - Vascultis (pulmonary, extrathoracic or systemic)-ANCA status unknown or negative) X.x X - Systemic/Distant conditions, syndromes and reactions
X.x - Subclinical ANCA positivity X.ac X - Systemic/Distant conditions, syndromes and reactions
X.ac - Anti-GBM antibody disease (Goodpasture-like or flare of preexisting GS) X.ah X - Systemic/Distant conditions, syndromes and reactions
X.ah - Granulomatosis with polyangiitis (typically ANCA pos.) - GPA flare XI.m XI - Miscellaneous
XI.m - Pulmonary emphysema - Lung cysts or bullae XI.ag XI - Miscellaneous
XI.ag - Vertebral compression fracture XI.ah XI - Miscellaneous
XI.ah - Fainting XI.an XI - Miscellaneous
XI.an - Disrupted lung surfactant function XIII.a XIII - Neoplastic conditions
XIII.a - Lung cancer XIV.c XIV - Hemoglobinopathies - Abnormal hemoglobin states (acquired)
XIV.c - Carboxyhemoglobinemia XV.k XV - Pathology
XV.k - Path: Desquamative interstitial pneumonia (DIP-pattern) XV.y XV - Pathology
XV.y - Path: Respiratory bronchiolitis (w/wo the RB-ILD-pattern) XV.z XV - Pathology
XV.z - Path: Obliterative (constrictive) bronchiolitis (see also IVc, IVn) XV.ay XV - Pathology
XV.ay - Path: Smoking-related interstitial fibrosis (SRIF). Respiratory bronchiolitis with fibrosis XV.bw XV - Pathology
XV.bw - Path: Airspace enlargement with fibrosis XVI.g XVI - Imaging
XVI.g - Imaging: Diffuse whiteout/alveolar shadowing (see also under IIb-ARDS) XVI.p XVI - Imaging
XVI.p - Imaging: Small irregular opacities - ILA - Diffuse reticulation - 'Dirty lung' XVI.ac XVI - Imaging
XVI.ac - Imaging: A generalized increase in lung density XVII.a XVII - Infections & related conditions
XVII.a - Respiratory tract infection incl. pneumonia
Trastuzumab
I.a - Pneumonitis (ILD), acute and/or severe (may cause ARDS) I.b I - Interstitial/parenchymal lung disease
I.b - Pneumonitis (ILD) I.c I - Interstitial/parenchymal lung disease
I.c - Eosinophilic pneumonia (pulmonary infiltrates and eosinophilia) I.d I - Interstitial/parenchymal lung disease
I.d - Organizing pneumonia pattern (an area or areas of consolidation on imaging) IV.a IV - Airway involvement
IV.a - Bronchospasm - Wheezing - Asthma IX.ab IX - Neuromuscular / CNS involvement - Disordered breathing during sleep
IX.ab - Guillain-Barré (or GB-like) syndrome (w/wo ARF) X.c X - Systemic/Distant conditions, syndromes and reactions
X.c - Capillary leak syndrome (CLS) X.f X - Systemic/Distant conditions, syndromes and reactions
X.f - Anaphylaxis-Anaphylactoid reaction (can be fatal) X.g X - Systemic/Distant conditions, syndromes and reactions
X.g - Hypersensitivity reaction (may manifest with fever and/or skin, throat or airway involvement) X.ae X - Systemic/Distant conditions, syndromes and reactions
X.ae - Antisynthetase antibodies (ASA) - ASA syndrome XII.a XII - Cardiovascular involvement / toxicity
XII.a - Left or biventricular dysfunction/failure XII.f XII - Cardiovascular involvement / toxicity
XII.f - Cardiomyopathy (acute, subacute, chronic) XII.l XII - Cardiovascular involvement / toxicity
XII.l - Cardiac arrhythmias or dysrhythmias (AF, VT, VF, TdP) XII.p XII - Cardiovascular involvement / toxicity
XII.p - QTc prolongation XII.ai XII - Cardiovascular involvement / toxicity
XII.ai - Cardiotoxicity
Vaccines
I.b - Pneumonitis (ILD) I.d I - Interstitial/parenchymal lung disease
I.d - Organizing pneumonia pattern (an area or areas of consolidation on imaging) I.y I - Interstitial/parenchymal lung disease
I.y - Progression, acceleration or exacerbation of preexisting ILD/fibrosis II.b II - Pulmonary edema - Acute lung injury - ARDS
II.b - ARDS - Acute lung injury IV.a IV - Airway involvement
IV.a - Bronchospasm - Wheezing - Asthma VIII.a VIII - Central-large-upper airway (incl. pharyngeal-nasal) involvement
VIII.a - Angioedema (may cause UAO, asphyxia and death) X.b X - Systemic/Distant conditions, syndromes and reactions
X.b - Antiphospholipid antibodies w/wo the APL syndrome X.d X - Systemic/Distant conditions, syndromes and reactions
X.d - Lupus - Lupus syndrome (see also Vd) X.f X - Systemic/Distant conditions, syndromes and reactions
X.f - Anaphylaxis-Anaphylactoid reaction (can be fatal) X.m X - Systemic/Distant conditions, syndromes and reactions
X.m - Vascultis (pulmonary, extrathoracic or systemic)-ANCA status unknown or negative) X.s X - Systemic/Distant conditions, syndromes and reactions
X.s - Vasculitis, pulmonary (w/wo AH), extrapulmonary, systemic: ANCA-positive
Vancomycin
I.c - Eosinophilic pneumonia (pulmonary infiltrates and eosinophilia) II.a II - Pulmonary edema - Acute lung injury - ARDS
II.a - Pulmonary edema, noncardiogenic (NCPE) IV.a IV - Airway involvement
IV.a - Bronchospasm - Wheezing - Asthma IV.f IV - Airway involvement
IV.f - Severe or catastrophic bronchospasm or asthma attack (can be fatal) V.n V - Pleural and/or pericardial involvement
V.n - Hemopericardium - Bloody pericardial effusion X.a X - Systemic/Distant conditions, syndromes and reactions
X.a - DRES syndrome - DRESS-like reaction X.f X - Systemic/Distant conditions, syndromes and reactions
X.f - Anaphylaxis-Anaphylactoid reaction (can be fatal) X.g X - Systemic/Distant conditions, syndromes and reactions
X.g - Hypersensitivity reaction (may manifest with fever and/or skin, throat or airway involvement) XII.m XII - Cardiovascular involvement / toxicity
XII.m - Cardiac- cardiorespiratory/pulmonary arrest XII.n XII - Cardiovascular involvement / toxicity
XII.n - Cardiovascular collapse - Cardiogenic shock - Hypotension
Venlafaxine
I.b - Pneumonitis (ILD) I.c I - Interstitial/parenchymal lung disease
I.c - Eosinophilic pneumonia (pulmonary infiltrates and eosinophilia) I.e I - Interstitial/parenchymal lung disease
I.e - Acute eosinophilic pneumonia (AEP) I.m I - Interstitial/parenchymal lung disease
I.m - ILD with a granulomatous component IV.a IV - Airway involvement
IV.a - Bronchospasm - Wheezing - Asthma X.a X - Systemic/Distant conditions, syndromes and reactions
X.a - DRES syndrome - DRESS-like reaction XI.r XI - Miscellaneous
XI.r - Death following exposure or poisoning XII.f XII - Cardiovascular involvement / toxicity
XII.f - Cardiomyopathy (acute, subacute, chronic) XII.g XII - Cardiovascular involvement / toxicity
XII.g - Coronary artery disease (acute) - Myocardial ischemia/infarction XII.l XII - Cardiovascular involvement / toxicity
XII.l - Cardiac arrhythmias or dysrhythmias (AF, VT, VF, TdP) XV.b XV - Pathology
XV.b - Path: Eosinophilic pneumonia (subacute or acute) (see also Ic)
Verapamil
II.a - Pulmonary edema, noncardiogenic (NCPE) II.b II - Pulmonary edema - Acute lung injury - ARDS
II.b - ARDS - Acute lung injury IV.a IV - Airway involvement
IV.a - Bronchospasm - Wheezing - Asthma XI.r XI - Miscellaneous
XI.r - Death following exposure or poisoning
Vinblastine
I.b - Pneumonitis (ILD) I.k I - Interstitial/parenchymal lung disease
I.k - Lung nodule or nodules I.l I - Interstitial/parenchymal lung disease
I.l - Diffuse alveolar damage (DAD) (see alsoo under IIb and XVf) II.a II - Pulmonary edema - Acute lung injury - ARDS
II.a - Pulmonary edema, noncardiogenic (NCPE) II.b II - Pulmonary edema - Acute lung injury - ARDS
II.b - ARDS - Acute lung injury IV.a IV - Airway involvement
IV.a - Bronchospasm - Wheezing - Asthma XII.g XII - Cardiovascular involvement / toxicity
XII.g - Coronary artery disease (acute) - Myocardial ischemia/infarction XV.f XV - Pathology
XV.f - Path: Diffuse alveolar damage (DAD-pattern) (see also IL)
Vindesine
I.b - Pneumonitis (ILD) II.a II - Pulmonary edema - Acute lung injury - ARDS
II.a - Pulmonary edema, noncardiogenic (NCPE) IV.a IV - Airway involvement
IV.a - Bronchospasm - Wheezing - Asthma IV.n IV - Airway involvement
IV.n - Obstructive airway dysfunction (see also IVc, XVx)
Vinorelbine
I.b - Pneumonitis (ILD) II.a II - Pulmonary edema - Acute lung injury - ARDS
II.a - Pulmonary edema, noncardiogenic (NCPE) II.b II - Pulmonary edema - Acute lung injury - ARDS
II.b - ARDS - Acute lung injury IV.a IV - Airway involvement
IV.a - Bronchospasm - Wheezing - Asthma X.f X - Systemic/Distant conditions, syndromes and reactions
X.f - Anaphylaxis-Anaphylactoid reaction (can be fatal) XII.m XII - Cardiovascular involvement / toxicity
XII.m - Cardiac- cardiorespiratory/pulmonary arrest